Cat. No. 2374
Alternative Name: L-768,242
Chemical Name: 1-(2,3-Dichlorobenzoyl)-5-methoxy-2
Biological ActivityPotent and selective CB2 receptor partial agonist (EC50 = 0.65 nM; maximum inhibition = 44.6%). Binds with high affinity to both human and rat CB2 receptors and displays ~ 1200-fold selectivity over CB1 (Ki values are 3.92 and 4772 nM for human recombinant CB2 and CB1 receptors respectively). Produces potent antihyperalgesic effects in several rodent models of pain.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Valenzano et al (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48 658. PMID: 15814101.
Clayton et al (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96 253. PMID: 11972997.
If you know of a relevant reference for GW 405833 please let us know.
Citations are publications that use Tocris products. Selected citations for GW 405833 include:
Marini et al (2013) Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol 169 887. PMID: 23711022.
McGuinness et al (2009) Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter β-arrestin assay. Cardiovasc Res 14 49. PMID: 19171920.
Do you know of a great paper that uses GW 405833 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GW 405833, supplier, Selective, high, affinity, CB2, receptor, partial, agonists, cannabinoids, Receptors, GW405833, L768242, cb2r, Tocris Bioscience, CB2 Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective CB2 partial agonist; orally biovailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.